A Phase 3 interventional study of Tenofovir disoproxil fumarate (TDF) tablets and Adefovir dipivoxil (ADV) tablets in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 20 sites in China. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2018-07-13.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing tenofovir in Hepatitis B, Chronic — none open to participants now, 1 under way, 1 of them phase 3. Tenofovir · Hepatitis B, Chronic.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, this one is the 6th largest by enrollment, is one of 6 that started in 2011, is one of 13 in phase 3, and was the 18th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →None of the 50 studies testing tenofovir in Hepatitis B, Chronic is open now. The open studies under Hepatitis B, Chronic, anywhere →
Tenofovir: first FDA approval 2001 (VIREAD), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 5 · Phase 3 13 · Phase 4 22
First in 2004; this study’s year is marked. 6 started in 2011.
This study's enrollment of 512 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 117 across the 50 interventional studies. Of the 37 that completed or were terminated, 17 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 50 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
30 studies in Hepatitis B, Chronic by GlaxoSmithKline: 1 open now, 2 under way, none of them phase 3. Of 28 finished, 18 (64%) have results posted.
Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 5th largest by enrollment of the 28 interventional ones that give a count, is one of 5 that started in 2011, is one of 8 in phase 3, and was the 12th registered.
GlaxoSmithKline’s Hepatitis B, Chronic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 50 studies testing tenofovir in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among GlaxoSmithKline’s 30 in Hepatitis B, Chronic:
This tab as a report to print or save as PDF → With an account.
This is a multi-centre, double blind, double dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. This study is designed to demonstrate the superiority of TDF 300mg QD over ADV 10mg QD in treating Chinese subjects with CHB (hepatitis B e antigen [HBeAg] positive subjects and HBeAg negative subjects). It will also provide long-term efficacy and safety data (up to 240 weeks) for TDF 300 mg administered once daily.
This is a multi-centre, double-blind, double-dummy, randomised, controlled study to evaluate the efficacy and safety of TDF 300mg QD versus ADV 10mg QD in Chinese subjects with CHB. Four hundred and ninety-four subjects with CHB (200 HBeAg positive subjects and 294 HBeAg negative subjects) will be randomised (1:1ratio) to either TDF 300mg QD or ADV 10mg QD treatment arms. The primary endpoint is the proportion of subjects with blood hepatitis B virus (HBV) deoxyribonucleic acid (DNA) \<400copies/mL (Roche COBAS Taqman HBV test) at Week 48 in HBeAg positive subjects with CHB and HBeAg negative subjects with CHB. This is a two-part study. The first treatment period (baseline to Week 48) will investigate the effects of TDF and ADV on safety and efficacy endpoints; dosing will be double-blind. This period will be followed by 192 weeks in which all subjects will receive open-label TDF (Week 49 to Week 240). Subjects will undergo regular safety and efficacy assessments every 4 weeks for the first 12 weeks followed by every 12 weeks for a total of up to 5 years.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
This study's enrollment of 512 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Browse Hepatitis B, Chronic studies →GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tenofovir disoproxil fumarate (TDF) tablets
Drug: Tenofovir disoproxil fumarate (TDF) tablets
Adefovir dipivoxil (ADV) tablets
Drug: Adefovir dipivoxil (ADV) tablets
white, almond-shaped, film-coated tablets containing 300mg of TDF
Also known as: TDF tablet
white to off-white, round, biconvex tablets containing 10mg of ADV
Also known as: ADV tablet
Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) <400 Copies/Milliliter (mL) at Week 48
The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) \<400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Week 48
Participants With HBV DNA <400 Copies/mL at Weeks 96, 144, 192, and 240
The number of participants with HBV DNA \<400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Weeks 96, 144, 192, and 240
Change From Baseline of Log 10 Copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240
Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline, Weeks 48, 96, 144, 192 and 240
Number of Participants With Alanine Aminotransferase (ALT) Normalization at Weeks 48, 96, 144, 192 and 240 in Participants Who Had Abnormal ALT at Baseline
Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter \[U/L\]). Values at Day 0 were considered as Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
Time frame: Baseline; Weeks 48, 96, 144, 192 and 240
Number of Participants With Histological Improvement at Weeks 48 and 240 Who Had a Baseline Knodell Necroinflammatory Score (KNS) >=2.
Histological improvement is defined as a reduction of \>=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS \>=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 \[best\] to 14 \[worst\]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation.
Time frame: Baseline; Week 48 and Week 240
Number of HBeAg-positive Participants Achieving HBeAg Loss and HBeAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240.
HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240.
Time frame: Weeks 24, 48, 96, 144, 192 and 240
Number of HBeAg-positive Participants Achieving Hepatitis B Surface Antigen (HBsAg) Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192 and 240
HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.
Time frame: Weeks 24, 48, 96, 144, 192 and 240
Number of HBeAg-negative Participants Achieving HBsAg Loss and HBsAg Seroconversion at Weeks 24, 48, 96, 144, 192, 240
HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.
Time frame: Weeks 24, 48, 96, 144, 192 and 240
Number of Participants Achieving Durable HBsAg Loss From Weeks 24 to Week 48
Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A "non-completers equal failures" approach was used for the analysis in ITT population.
Time frame: Week 24 to Week 48
Number of Participants Achieving Durable HBsAg Loss From Weeks 96 to Week 240
Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A "non-completers equal failures" approach was used for the analysis in ITT population.
Time frame: Week 96 to Week 240
Number of Participants With Virological Breakthrough at Weeks 48, 96, 144, 192 and 240
The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by \>= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A "non-completers equal failures" approach was used for the analysis in ITT population.
Time frame: Weeks 48, 96, 144, 192 and 240
Number of Participants With Any Serious Adverse Event (SAE) and Any Non-serious Adverse Event (AE)
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported.
Time frame: Up to Week 240 treatment period and 24 weeks follow-up visit off treatment
Number of Participants With the Indicated Grade 3 and Grade 4 Treatment-emergent (TE) Laboratory Abnormalities (LAs)
TE grade 3 or grade 4 LAs are defined as values that increase by \>=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase.
Time frame: Up to Week 240
Number of Participants With the Indicated Treatment-emergent Laboratory Abnormalities for Serum Creatinine and Serum Phosphorus
The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, \> 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, \>177 to 265 µmoles/Liter, Grade 3, \>265 to 530 µmoles/Liter, Grade 4, \>530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to \<0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to \<0.63 mmoles/L, Grade 4, \<0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point.
Time frame: Up to Week 240
Number of Participants in the Indicated Category for Renal Laboratory Abnormalities
The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. "Confirmed" is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade.
Time frame: Up to Week 240
This was a 2 sequential treatment period study. In first period (double-blinded),participants received tenofovir disoproxil fumarate (TDF) 300 milligram (mg) once daily (QD) or adefovir dipivoxil (ADV) 10 mg QD for 48 Weeks. In second period (open-label single treatment), participants received TDF 300 mg QD for additional 192 Weeks.
| Milestone | TDF-TDF | ADV-TDF |
|---|---|---|
| Started | 257 | 255 |
| Completed | 229 | 228 |
| Not completed | 28 | 27 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Protocol violation | 2 | 3 |
| Withdrew: Withdrawal by subject | 5 | 9 |
| Withdrew: Lost to follow-up | 14 | 12 |
| Withdrew: Pregnancy | 2 | 1 |
| Withdrew: Participant reached stopping critera | 2 | 0 |
| Withdrew: Participant stopped medication | 1 | 1 |
| Withdrew: Participant refused return to hospital | 1 | 0 |
The number of participants with Hepatitis B Virus (HBV) deoxyribonucleic acid (DNA) \<400 copies/milliliter (mL) at Week 48 in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | TDF 300 mg | ADV 10 mg |
|---|---|---|
| HBeAg-positive, n=103, 99 | 79 | 18 |
| HBeAg-negative, n=154, 153 | 149 | 109 |
The number of participants with HBV DNA \<400 copies/mL in the hepatitis B e antigen (HBeAg)-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually, a negative result indicates that the participant has lower levels of virus in the blood and is less infectious. Week 96, 144, 192, and 240 data are not yet available, as this report includes data up to and including Week 48. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 96, HBeAg-positive, n=103, 99 | 95 | 92 |
| Week 96, HBeAg-negative, n=154, 153 | 144 | 143 |
| Week 144, HBeAg-positive, n=103, 99 | 97 | 95 |
| Week 144, HBeAg-negative, n=154,153 | 144 | 145 |
| Week 192, HBeAg-positive, n=103,99 | 94 | 93 |
| Week 192,HBeAg-negative, n=154,153 | 144 | 141 |
| Week 240, HBeAg-positive, n=103,99 | 87 | 87 |
| Week 240, HBeAg-negative, n=154,153 | 138 | 137 |
Change from Baseline of log 10 copies/mL HBV DNA at Weeks 48, 96, 144, 192 and 240 in the HBeAg-positive and HBeAg-negative population was assessed. HBeAg is a viral protein that is secreted by hepatitis B-infected cells. It is associated with chronic hepatitis B infections and is used as a marker of active viral disease and a participant's degree of infectiousness. A positive result indicates that the participant has high levels of virus in the blood and greater infectiousness. Usually a negative result indicates that the participant has lower levels of virus in the blood and less infectious. Values at Day 0 were considered as Baseline values. Change from Baseline was calculated as post Baseline values minus Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| log10 copies/mL | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 48,HBeAg-positive, n=102, 97 | -6.4 ± 0.86 | -4.4 ± 1.69 |
| Week 48,HBeAg-negative, n=151, 148 | -4.9 ± 1.16 | -4.3 ± 1.31 |
| Week 96, HBeAg-positive, n=101, 97 | -6.5 ± 0.86 | -6.5 ± 0.81 |
| Week 96, HBeAg-negative, n=147,148 | -4.9 ± 1.26 | -4.8 ± 1.17 |
| Week 144, HBeAg-postive, n=100, 96 | -6.6 ± 0.86 | -6.5 ± 0.80 |
| Week 144, HBeAg-negative, n=145, 146 | -4.9 ± 1.16 | -4.9 ± 1.09 |
| Week 192, HBeAg-positive, n=97,93 | -6.6 ± 0.86 | -6.6 ± 0.81 |
| Week 192, HBeAg-negative, n=145,145 | -4.9 ± 1.17 | -4.8 ± 1.14 |
| Week 240, HBeAg-positive, n=91,90 | -6.6 ± 1.01 | -6.5 ± 0.79 |
| Week 240, HBeAg-negative, n=138,138 | -4.9 ± 1.16 | -4.9 ± 1.07 |
Participants who had abnormal ALT at Baseline and had normalized ALT at Weeks 48, 96, 144, 192 and 240 were assessed. This report includes data up to and including Weeks 48, 96, 144, 192 and 240. An increased level of ALT is referred to as abnormal ALT (the normal range is 0 to 48 units per liter \[U/L\]). Values at Day 0 were considered as Baseline values. A "non-completers equal failures" approach is used for the analysis in ITT population. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 48, HBeAg-positive, n=102, 97 | 88 | 83 |
| Week 48, HBeAg-negative, n=136, 132 | 120 | 116 |
| Week 96, HBeAg-positive, n=102, 97 | 93 | 88 |
| Week 96, HBeAg-negative, n=136,132 | 126 | 118 |
| Week 144, HBeAg-positive, n=102, 97 | 92 | 87 |
| Week 144, HBeAg-negative, n=136, 132 | 123 | 119 |
| Week 192, HBeAg-positive, n=102, 97 | 89 | 79 |
| Week 192, HBeAg-negative, n=136,132 | 125 | 118 |
| Week 240, HBeAg-positive, n=102, 97 | 82 | 80 |
| Week 240, HBeAg-negative, n=136,132 | 119 | 111 |
Histological improvement is defined as a reduction of \>=2 points in the KNS with no increase in fibrosis at Week 48 and Week 240 in participants with Baseline KNS \>=2 which was derived from the American Association for the Study of Liver Diseases Practice Guidelines for Management of Chronic Hepatitis B (2009) and the European Association for the Study of the Liver Clinical Practice Guidelines Management of chronic hepatitis B virus infection (2012). The Knodell scale consists of 5 domains: periportal +/- bridging necrosis (scored from best to worst: 0, 1, 3, 4, 5, 6, or 10); intralobular degeneration and focal necrosis (0 to 4); portal inflammation (0 to 4); and fibrosis (0 to 4). The necroinflammatory score (ranging from 0 \[best\] to 14 \[worst\]) is the combined score for necrosis (0 to 10) plus inflammation (0 to 4; the participant is scored for only one inflammatory condition). Liver biopsy slides within 6 months prior to randomization could be accepted as Baseline evaluation.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 48, HBeAg-positive, n=38, 49 | 31 | 39 |
| Week 48, HBeAg-negative, n=45, 50 | 32 | 34 |
| Week 240, HBeAg-positive, n=38, 49 | 5 | 2 |
| Week 240, HBeAg-negative, n=45, 50 | 8 | 4 |
HBeAg loss is defined as a negative HBeAg result for those participants who were HBeAg positive at Baseline. Seroconversion to anti-HBe is defined as HBeAg loss and a positive anti-HBe result. This report includes data up to and including Weeks 24, 48, 96, 144, 192 and 240.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 24, HBeAg loss | 15 | 4 |
| Week 24, HBeAg seroconversion | 14 | 4 |
| Week 48, HBeAg loss | 18 | 10 |
| Week 48, HBeAg seroconversion | 16 | 9 |
| Week 96, HBeAg loss | 37 | 21 |
| Week 96, HBeAg seroconversion | 32 | 18 |
| Week 144, HBeAg loss | 37 | 24 |
| Week 144, HBeAg seroconversion | 33 | 20 |
| Week 192, HBeAg loss | 43 | 31 |
| Week 192, HBeAg seroconversion | 33 | 24 |
| Week 240, HBeAg loss | 43 | 36 |
| Week 240, HBeAg seroconversion | 33 | 28 |
HBsAg loss is defined as negative HBsAg results for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 24, HBsAg loss | 0 | 0 |
| Week 24, HBsAg seroconversion | 0 | 0 |
| Week 48, HBsAg loss | 0 | 0 |
| Week 48, HBsAg seroconversion | 0 | 0 |
| Week 96, HBsAg loss | 0 | 0 |
| Week 96, HBsAg seroconversion | 0 | 0 |
| Week 144, HBsAg loss | 1 | 0 |
| Week 144, HBaAg seroconversion | 0 | 0 |
| Week 192, HBsAg, loss | 1 | 0 |
| Week 192, HBsAg, seroconversion | 0 | 0 |
| Week 240, HBsAg loss | 1 | 0 |
| Week 240 HBsAg seroconversion | 0 | 0 |
HBsAg loss is defined as a negative HBsAg result for those participants with who were HBsAg positive at Baseline. Seroconversion to anti-HBs is defined as HBsAg loss and a positive anti-HBs result. This report includes data up to and including Week 240.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 24, HBsAg loss | 0 | 0 |
| Week 24, HBsAg seroconversion | 0 | 0 |
| Week 48, HBsAg loss | 0 | 0 |
| Week 48, HBsAg seroconversion | 0 | 0 |
| Week 96, HBsAg loss | 0 | 0 |
| Week 96, HBsAg seroconversion | 0 | 0 |
| Week 144, HBsAg loss | 0 | 1 |
| Week 144, HBsAg seroconversion | 0 | 1 |
| Week 192, HBsAg loss | 0 | 0 |
| Week 192, HBsAg seroconversion | 0 | 0 |
| Week 240, HBsAg loss | 0 | 0 |
| Week 240, HBsAg seroconversion | 0 | 0 |
Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart. This report includes data up to and including Week 48. A "non-completers equal failures" approach was used for the analysis in ITT population.
| Participants | TDF 300 mg | ADV 10 mg |
|---|---|---|
| HBeAg-positive, n =100, 97 | 0 | 0 |
| HBeAg-negative, n=150, 147 | 0 | 0 |
Durable HBsAg loss is defined as the loss of HBsAg and no detectable HBV DNA and ALT normalization at any three consecutive visits at least 12 Weeks apart from Week 96 to 240. This report includes data up to and including Week 240. A "non-completers equal failures" approach was used for the analysis in ITT population.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| HBeAg-positive, n= 88, 90 | 1 | 0 |
| HBeAg-negative, n = 132, 137 | 0 | 1 |
The number of HBeAg-positive and HBeAg-negative participants who had virological breakthrough at Weeks 48, 96, 144, 192 and 240 were assessed. Virological breakthrough is defined by \>= one log increase in HBV DNA from NADIR (as determined by two sequential HBV DNA measurements at least one month apart or last on treatment measurement). A "non-completers equal failures" approach was used for the analysis in ITT population.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Week 48,HBeAg-Positive, n=103, 99 | 0 | 4 |
| Week 48, HBeAg-Negative, n=154, 153 | 0 | 2 |
| Week 96, HBeAg-positive, n=103, 99 | 0 | 4 |
| Week 96, HBeAg-negative, n=154, 153 | 2 | 3 |
| Week 144, HBeAg-positive, n=103, 99 | 0 | 7 |
| Week 144, HBeAg-negative, n=154, 153 | 3 | 4 |
| Week 192, HBeAg-positive, n=103, 99 | 0 | 7 |
| Week 192, HBeAg-negative, n=154, 153 | 3 | 5 |
| Week 240, HBeAg-positive, n=103, 99 | 4 | 11 |
| Week 240, HBeAg-negative, n=154, 153 | 3 | 8 |
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is Grade 4 (life threatening or disabling). Participants with any non-serious AEs and SAEs has been reported.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Non-serious AE | 140 | 121 |
| SAE | 12 | 20 |
TE grade 3 or grade 4 LAs are defined as values that increase by \>=1 grade from Baseline (Day 0) to Grade 3 (severe) or 4 (potentially life threatening) at any post-Baseline value. The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Laboratory parameters assessed included Sodium for hyponatremia and hypernatremia; Potassium for hypokalemia and hyperkalemia; glucose for hypoglycemia and hyperglycemia non-fasting; Phosphate for hypophosphatemia; alanine aminotransferase/aspartate aminotransferase, bilirubin, creatinine kinase, hemoglobin, platelets, neutrophils, lymphocytes, prothrombin time and amylase.
| participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Sodium | 2 | 0 |
| Phosphate | 2 | 3 |
| Alanine aminotransferase | 19 | 14 |
| Aspartate aminotransferase | 10 | 6 |
| Bilirubin | 1 | 1 |
| Creatine kinase | 6 | 4 |
| Hemoglobin | 4 | 5 |
| Platelets | 4 | 3 |
| Neutrophils | 6 | 4 |
| Prothrombin time | 10 | 17 |
| Potassium | 1 | 0 |
| Glucose | 1 | 2 |
| Lymphocytes | 2 | 3 |
| Amylase | 1 | 2 |
The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was referred for grading. Serum creatinine: Grade 1, \> 133 to 177 micromoles per Liter (µmoles/Liter), Grade 2, \>177 to 265 µmoles/Liter, Grade 3, \>265 to 530 µmoles/Liter, Grade 4, \>530 µmoles/Liter. Serum phosphorus: Grade 2, 0.63 to \<0.80 millimoles per Liter (mmoles/L), Grade 3, 0.31 to \<0.63 mmoles/L, Grade 4, \<0.31 mmoles/L. The normal range for serum phosphorus was 0.8 to 1.45 mmoles/L; the upper limit for a Grade 2 abnormality is 0.80 mmoles/L. Therefore, no Grade 1 abnormalities could be attributed, as values were contained within the normal range. NA indicates the value was not available for the indicated time point.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Serum creatinine, Grade 1 | 0 | 1 |
| Serum creatinine, Grade 2 | 0 | 0 |
| Serum creatinine, Grade 3 | 0 | 0 |
| Serum creatinine, Grade 4 | 0 | 0 |
| Serum phosphorus, Grade 1 | NA | NA |
| Serum phosphorus, Grade 2 | 42 | 55 |
| Serum phosphorus, Grade 3 | 2 | 3 |
| Serum phosphorus, Grade 4 | 0 | 0 |
The Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities, version 21, September 2011 was used for grading. "Confirmed" is defined as two consecutive visits. mg=milligrams. dL=deciliter, G= Grade.
| Participants | TDF-TDF | ADV-TDF |
|---|---|---|
| Creatinine increase of 0.5 mg/dL above Baseline | 1 | 0 |
| Confirmed creatinine >=2.0 mg/dL | 0 | 0 |
| Confirmed clearance <50 milliliters/minute | 0 | 0 |
| Confirmed phosphorus G 3/4 abnormality, <2.0 mg/dL | 3 | 0 |
Collected over Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study treatment up to 240 weeks treatment period and 24 weeks follow-up visit off treatment.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TDF-TDF | 1/257 (0.4%) | 12/257 (4.7%) | 140/257 (54.5%) |
| ADV-TDF | 0/252 (0%) | 20/252 (7.9%) | 121/252 (48%) |
| Event | TDF-TDF | ADV-TDF |
|---|---|---|
| Hepatic cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/257 | 3/252 |
| CholangiocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/257 | 2/252 |
| UreterolithiasisRenal and urinary disorders | 0/257 | 2/252 |
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/257 | 0/252 |
| Abdominal pain upperGastrointestinal disorders | 0/257 | 1/252 |
| HepatitisHepatobiliary disorders | 0/257 | 1/252 |
| Cubital tunnel syndromeNervous system disorders | 0/257 | 1/252 |
| Miscarriage of partnerSocial circumstances | 0/257 | 1/252 |
| Lymphoid tissue hyperplasiaBlood and lymphatic system disorders | 0/257 | 1/252 |
| Angina pectorisCardiac disorders | 0/257 | 1/252 |
| Event | TDF-TDF | ADV-TDF |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 34/257 | 25/252 |
| Alanine aminotransferase increasedInvestigations | 16/257 | 8/252 |
| NephrolithiasisRenal and urinary disorders | 5/257 | 13/252 |
| Hepatic steatosisHepatobiliary disorders | 11/257 | 11/252 |
| NasopharyngitisInfections and infestations | 8/257 | 8/252 |
| Blood creatine phosphokinase increasedInvestigations | 7/257 | 8/252 |
| Gallbladder polypHepatobiliary disorders | 6/257 | 4/252 |
| Renal cystRenal and urinary disorders | 6/257 | 3/252 |
| Abdominal pain upperGastrointestinal disorders | 3/257 | 5/252 |
| AstheniaGeneral disorders | 4/257 | 5/252 |
Baseline data were collected in members of the Intent-to-Treat Population, comprised of all randomized participants who received at least one dose of study medication.
| Age, Continuous(Years) | TDF-TDF | ADV-TDF | Total |
|---|---|---|---|
| Mean | 36.1 ± 10.48 | 36.4 ± 10.43 | 36.3 ± 10.44 |
| Sex: Female, Male(Participants) | TDF-TDF | ADV-TDF | Total |
|---|---|---|---|
| Female | 43 | 42 | 85 |
| Male | 214 | 210 | 424 |
| Race/Ethnicity, Customized(participants) | TDF-TDF | ADV-TDF | Total |
|---|---|---|---|
| Asian - East Asian Heritage | 257 | 252 | 509 |
Ran from Mar 2011 to primary completion in Oct 2012, 18 months.
Results were first posted in Aug 2013, 9 months after primary completion.
Of 24 phase 3 interventional studies under Hepatitis B, Chronic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 47. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenofovir